Kidneys and MR Urography

Magnetic Resonance Imaging Clinics of North America

Volumn 15, Issue 3, 2007, Pages 373-382

  Leyendecker, John R ^a   Childs, David D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; GADOBENIC ACID; GADOLINIUM PENTETATE;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FUNCTIONAL ASSESSMENT; HUMAN; IMAGE PROCESSING; IMAGING SYSTEM; INTRAVENOUS UROGRAPHY; KIDNEY DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SIGNAL NOISE RATIO; URINARY TRACT DISEASE; UROGRAPHY;

EID: 34548773926     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2007.06.007     Document Type: Review

References (37)

1. Schindera S., Merkle E., Dale B., et al. Abdominal magnetic resonance imaging at 3.0T: what is the ultimate gain in signal-to-noise ratio?. Acad Radiol 13 (2006) 1236-1243
2. Nolte-Ernsting C., Adam G., and Bücker A. Contrast-enhanced magnetic resonance urography: first experimental results with a polymeric gadolinium bloodpool agent. Invest Radiol 32 (1997) 418-423
3. El-Diasty T., Mansour O., and Farouk A. Diuretic contrast-enhanced magnetic resonance urography versus intravenous urography for depiction of nondilated urinary tracts. Abdom Imaging 28 (2003) 135-145
4. Ergen F.B., Hussain H.K., Carlos R.C., et al. 3D excretory MR urography: improved image quality with intravenous saline and diuretic administration. J Magn Reson Imaging 25 (2007) 783-789
5. Tsubota M., Takahara T., Nitatori T., et al. Utility of cine MR urography of the urinary tract and comparison with static MR urography. Radiat Med 22 (2004) 212-217
6. Merkle E.M., Haugan P.A., Thomas J., et al. 3.0T versus 1.5T MR cholangiography: a pilot study. AJR Am J Roentgenol 186 (2006) 516-521
7. O'Regan D.P., Fitzgerald J., Allsop J., et al. A comparison of MR cholangiopancreatography at 1.5 and 3.0 Tesla. Br J Radiol 78 (2005) 894-898
8. Schindera S.T., Miller C.M., Ho L.M., et al. Magnetic resonance (MR) cholangiography: quantitative and qualitative comparison of 3.0 Tesla with 1.5Tesla. Invest Radiol 42 (2007) 399-405
9. Sasaki M., Shibata E., Kanbara Y., et al. Enhancement effects and relaxivities of gadolinium-DTPA at 1.5 versus 3 Tesla: a phantom study. Magn Reson Med Sci 4 (2005) 145-149
10. Trattnig S., Pinker K., Ba-Ssalamah A., et al. The optimal use of contrast agents at high field MRI. Eur Radiol 16 (2006) 1280-1287
11. Nöbauer-Huhmann I.M., Ba-Ssalamah A., Mlynarik V., et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 Tesla versus 1.5 Tesla. Invest Radiol 37 (2002) 114-119
12. Krautmacher C., Willinek W.A., Tschampa H., et al. Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0T compared with 1.5T-initial experience. Radiology 237 (2005) 1014-1019
13. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
14. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
15. Khurana A., Runge V.M., Narayanan M., et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42 (2007) 139-145
16. Broome D.R., Girguis M.S., Baron P.W., et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188 (2007) 586-592
17. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 242 (2007) 148-157
18. Kanal E., Barkovich A.J., Bell C., et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188 (2007) 1447-1474
19. Pintaske J., Martirosian P., Graf H., et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 41 (2006) 213-221
20. Fukatsu H. 3T MR for clinical use: update. Magn Reson Med Sci 2 (2003) 37-45
21. Merkle E., Dale B., and Paulson E. Abdominal MR imaging at 3T. Magn Reson Imaging Clin N Am 14 (2006) 17-26
22. Bernstein M., Huston III J., and Ward H. Imaging artifacts at 3.0T. J Magn Reson Imaging 24 (2006) 735-746
23. Tanenbaum L. Clinical 3T MR imaging: mastering the challenges. Magn Reson Imaging Clin N Am 14 (2006) 1-15
24. Bottomley P., Foster T., Argersinger R., et al. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 11 (1984) 425-448
25. Stanisz G., Odrobina E.E., Pun J., et al. T1, T2 relaxation and magnetization transfer in tissue at 3T. Magn Reson Med 54 (2005) 507-512
26. Schmitt M, Feiweier T, Horger W, et al. Improved uniformity of RF-distribution in clinical whole body imaging at 3T by means of dielectric pads. Presented at the 12th Annual Meeting of ISMRM. Kyoto, Japan, May 15-21, 2004.
27. Sreenivas M., Lowry M., Gibbs P., et al. A simple solution for reducing artefacts due to conductive and dielectric effects in clinical magnetic resonance imaging at 3 T. Eur J Radiol 62 (2007) 143-146
28. Pruessmann K.P. Parallel imaging at high field strength: synergies and potential. Top Magn Reson Imaging 15 (2004) 237-244
29. Busse R. Reduced RF power without blurring: correcting for modulation of refocusing flip angle in FSE sequences. Magn Reson Med 51 (2004) 1031-1037
30. Hennig J., and Scheffler K. Hyperechoes. Magn Reson Med 46 (2001) 6-12
31. Michaely H.J., Herrmann K.A., Nael K., et al. Functional renal imaging: nonvascular renal disease. Abdom Imaging 32 (2007) 1-16
32. Tumkur S.M., Vu A.T., Li L.P., et al. Evaluation of intra-renal oxygenation during water diuresis: a time-resolved study using BOLD MRI. Kidney Int 70 (2006) 139-143
33. Maril N., Rosen Y., Reynolds G., et al. Sodium MRI of the human kidney at 3 Tesla. Magn Reson Med 56 (2006) 1229-1234
34. Michaely H., Nael K., Schoenberg S.O., et al. Renal perfusion: comparison of saturation-recovery TurboFLASH measurements at 1.5 T with saturation-recovery TurboFLASH and time-resolved echo-shared angiographic technique (TREAT) at 3.0T. J Magn Reson Imaging 24 (2006) 1413-1419
35. Boss A., Martirosian P., Graf H., et al. High resolution MR perfusion imaging of the kidneys at 3 Tesla without administration of contrast media. Rofo 177 (2005) 1625-1630
36. Katz-Brull R., Rofsky N.M., and Lenkinski R.E. Breathhold abdominal and thoracic proton MR spectroscopy at 3T. Magn Reson Med 50 (2003) 461-467
37. Katz-Brull R., Rofsky N.M., Morrin M.M., et al. Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. Am J Physiol Renal Physiol 288 (2005) F637-F641